Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis (Q44283427)

1 December 2017

0 references

Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis (English)

1 reference

1 December 2017

1 reference

1 reference

1 reference

1 reference

Philippe Chevalier

1

1 reference

1 December 2017

Alexis Durand-Dubief

2

1 reference

1 December 2017

Haran Burri

3

1 reference

1 December 2017

Michel Cucherat

4

1 reference

1 December 2017

Gilbert Kirkorian

5

1 reference

1 December 2017

Paul Touboul

6

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

Journal of the American College of Cardiology

1 December 2017

published in

1 reference

1 December 2017

volume

41

1 reference

1 December 2017

issue

2

1 reference

1 December 2017

page(s)

255-262

1 reference

Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Efficacy of flecainide for the reversion of acute onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Intravenous amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Cellular electropharmacology of amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Acute electrophysiologic effects of amiodarone in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Pharmacokinetics of amiodarone: implications for drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Hemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

Adverse effects of amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902705-5

7 January 2021

10.1016/S0735-1097(02)02705-5

Identifiers

DOI

1 reference

1 December 2017

1 reference